Rilzabrutinib

Phase 3

Sanofi (SNY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

SNYPhase 3$50.8B

Rilzabrutinib Phase 3 Est. Readout

Rilzabrutinib• Immune Thrombocytopenia192

Q3 2027~QConfirmedSTALE

CT.gov

00%

Q4 '26

SNYPhase 3$50.8B

rilzabrutinib Phase 3 Est. Readout

Rilzabrutinib• Immune Thrombocytopenia4

Q4 2026~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Immune Thrombocytopenia

View Full Landscape

Drug Information

Target Indication

Immune Thrombocytopenia

Clinical Trial

NCT04562766

Last updated: 12/11/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/22/2025

Wayrilz

Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Fexofenadine, Comparator = MontelukastPhase 3

Asthma

Teriflunomide 14 MG Oral Tablet [Aubagio]Phase 3

Multiple Sclerosis

Dupilumab/DupixentPhase 3

Asthma

dronedaronePhase 3

Atrial Fibrillation

AvidinPhase 3

Embolism

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts